College of Pharmacy

7 Greenhouse Road Kingston, RI 02881

pharmcol@etal.uri.edu – Office: 401.874.2761 Fax: 401.874.2181

URI
Think Big, We Do.
Rhode Island Seal

Clinical Pharmacokinetics Research

Fatemeh Akhlaghi, Pharm.D., Ph.D.

Located in Lab Module 490 on Level 4 of the Pharmacy building

The Clinical Pharmacokinetics Research Laboratory is specialized in the areas of effect of disease states on drug disposition, pharmacokinetics and pharmacodynamics (PK/PD) modeling, and therapeutic drug monitoring (TDM). Located at the Kingston Campus of the University of Rhode Island, this laboratory is equipped with High Performance Liquid Chromatography (HPLC-UV, Hitachi) and ABI 3200 LC-Tandem Mass Spectrometry (LC-MS/MS, AB Sciex), a Xevo™ TQ MS (LC-MS/MS Waters), and a range of other instruments through RI-INBRE centralized core facility. We have established and validated different analytical methods for determination of immunosuppressive agents (i.e. cyclosporine, tacrolimus, sirolimus and mycophenolic acid) and other medications (listed below). In addition, we specialize in the measurement of free (unbound) drug concentration, either in plasma or oral fluids (saliva), and have established methods for determination of contrast media agents, iohexol or iodixanol, useful for accurate estimation of Glomerular Filtration Rate (GFR).

Concentration of total drug and metabolites in biological fluids for in vitro metabolism studies

Acetaminophen glucuronide, sulfate and glutathione metabolites (under development)
AZT (3′-azido-3′-deoxythymidine) glucuronidation as probe for UGT2B7 activity (LC-MS/MS)
Chlorzoxazone hydroxylation as probe for P450 2E1 activity (LC-MS/MS)
Cortisol metabolite (6 beta hydroxy cortisol) and free cortisol concentration in urine (under development)
Estradiol-glucuronidation as probe for UGT1A1 activity (HPLC-UV)
Midazolam, 1′-OH and 4-OH midazolam determination as probe for P450 3A4/5 activity (LC-MS/MS)

 


index_clip_image001_0008

URI Professor Wins Grant to Study Possible Alcoholism Treatment

DR. FATEMEH AKHLAGHI, a University of Rhode Island professor of biomedical and pharmaceutical sciences, has received $1.65 million from the National Institutes of Health to study a new treatment for alcoholism in collaboration with Dr. Lorenzo Leggio of the National Institute on Alcohol Abuse and Alcoholism.

Diabetes patients on Lipitor needed for URI study

Diabetes patients on Lipitor needed for URI study

Plus you can earn an easy $40. KINGSTON, R.I. – September 10, 2010 – If you have diabetes and are taking Lipitor™ you might want to join a University of Rhode Island College of Pharmacy study that could help you and others with the disease. Fatemeh Akhlaghi, URI associate professor of biomedical and pharmaceutical sciences, […]

URI pharmacy researcher seeks participants

URI pharmacy researcher seeks participants

Lipitor metabolism study in patients with diabetes KINGSTON, R.I. – December 1, 2009 – A researcher in the University of Rhode Island’s College of Pharmacy is seeking subjects for a study focusing on the metabolism and side effects of Lipitor™ on patients with diabetes. Fatemeh Akhlaghi, URI associate professor of biomedical and pharmaceutical sciences, has […]

index_clip_image001_0008

URI pharmacy professor has patent pending for pain-free method of monitoring drug levels in transplant patients

Use of saliva would reduce need for blood tests KINGSTON, R.I. – March 27, 2009 –The U.S. Patent and Trademark Office is reviewing a University of Rhode Island pharmacy professor’s proposal to use saliva as a non-invasive way to monitor concentrations of anti-rejection drugs in patients that undergo transplants. Associate Professor of Pharmacy Fatemeh Akhlaghi […]

Copyright © 2014 University of Rhode Island.

The University of Rhode Island
Think Big, We Do.
A-ZDirectoryContact UsJump to top